Yervoy/Nivolumab Combo Keying Bristol’s Immuno-Oncology R&D Strategy
This article was originally published in The Pink Sheet Daily
At the Morgan Stanley Healthcare Conference, recently promoted CSO Francis Cuss spoke about Bristol’s plans to test a combination of Yervoy and nivolumab in a variety of tumor types. The pharma’s near-term goals also center on label expansion for Eliquis and filing the first all-oral combination regimen for hepatitis C in Japan.
You may also be interested in...
The oral anticoagulant generated just $12 million in sales in its first full quarter since it launched in the U.S., lower than expected. Bristol will increase investment in the brand to drive growth.
Long-time senior VP of R&D Francis Cuss will succeed Elliott Sigal as Bristol’s head of R&D on July 1, following a transition period. In an investor call, Cuss indicated no great change in strategy but acknowledged an ongoing need to evolve corporate thinking and capability.
The European Safety Authority is running consultations on its proposals to set safe intake levels from foods, including dietary supplements, for iron and vitamin A.